References
- BERNINK, J. J. L. M., PRAGER, G., SCHELLING, A. and KOBRIN, I., 1996, Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40–5967). A new generation of calcium antagonists? Hypertension, 27, 426–432.
- CLOZEL J-P., BANKEN, L. and OSTERR1EDER, W., 1989, Effects of Ro 40–5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. Journal of Cardiovascular Pharmacology, 14, 713–721.
- CLOZEL, J.-P., 0 STERRIEDER, W., KLEINBLOESSEM C. H., WELKER, H. A., SCHLA PPI, B., TUDOR, R., HEFTI, H., SCHMITT, R. and EGGERS, H., 1991, Ro 40–5967: a new non-dihydropyridine calcium antagonist. Cardiovascular Drug Reviews 9, 4–17.
- MISHRA, S. K. and HERMAMEYER, K., 1994, Selective inhibition of T-type Ca2+ channels by Ro 40-5967. Circulation Research 75, 144–148.
- OPERIL S. and CALHOUN, D. A., 1991, The calcium antagonist in the 1990s: an overview. American Journal of Hypertension, 4, 396S–405S.
- OSTERR1EDER, W. and HoLoc, M., 1989, In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action, Journal of Cardiovascular Pharmacology 13, 754–759.
- PORTEGlES, M. C. M., SCHMITT, R., KRAAU, C. J., BRAAT, S. H. J. G., GUSSNER, A., HAGERMEIJER, F., POZENEL, H., PRAGER, G., VlERSMA, J. W., VAN DER WALL, E. E., KLEINBLOESSEM, C. H. and LlE, K. E., 1991, Lack of negative inotropic effects of the new calcium antagonist Ro 40–5967 in patients with chronic stable angina pectoris. Journal of Cardiovascular Pharmacology 18, 746–751.
- RUTLEDGE, A. and TRIGGLE, D. J., 1995, The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue. European Journal of Pharmacology, 290, 155–158.
- TRIGGLE, D. J., 1991, Sites, mechanism of action and differentiation of calcium channel antagonists. American Journal of Hypertension, 4, 422S–429S.
- WELKER, H. A., EGGERS, H., KLEINBLOESSEM, CH., ERB, K., BREITHAUPT, K., BUTZER, R. and BELZ, G. G., 1989, Ro 40–5967: pharmacokinetics of a new calcium antagonist. European Journal of Clinical Pharmacology, 36, (suppl.), A304.
- WILTSHIRE, H. R., HARRIS, S. R., PRIOR, K. J., KOZLOWSKI, U. M. and WORTH, E., 1992, Metabolism of calcium antagonist Ro 40-5967: a case history of the use of diode-array UV spectroscopy and thermospray-mass spectrometry in the elucidation of a complex metabolic pathway. Xenobiotica, 22, 837–857.
- WILTSHIRE, H. R., SUTTON, B. M., HEEPS, G., BETTY, A. M., ANGUS, D. A., MADIGAN, M. J. and SHARP, S. R., 1997, The metabolism of the calcium antagonist, mibefradil (POSICORTM, Ro 40-5967). Part II, metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man. Xenobiotica, 27, 539–566.
- WOOD, A., 1989, Calcium antagonists: pharmacological differences and similarities, Circulation, 80 (suppl. IV), IV.84–88.